Amgen
Compare Amgen…Large-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
AmgenLarge-cap biopharma. MariTide: antibody-peptide conjugate combining GLP-1 agonism with GIPR antagonism, monthly or less frequent dosing. Phase 3 readout expected late 2026.
Basic shares represent total shares issued. Diluted shares include potential shares from stock options, convertible securities, and other equity awards.
Q2 2016 — Q1 2026